Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v11-EN Version v11-EN
Language English English
Date Updated 2021-12-09 2021-12-09
Drug Identification Number 02264315 02264315
Brand name HEPARIN SODIUM INJECTION, USP HEPARIN SODIUM INJECTION, USP
Common or Proper name Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 10 mL Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 10 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients HEPARIN SODIUM HEPARIN SODIUM
Strength(s) 1000UNIT 1000UNIT
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS
Packaging size 10 mL 10 mL
ATC code B01AB B01AB
ATC description ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2021-11-15 2021-11-15
Actual start date 2021-11-15 2021-11-15
Estimated end date 2021-12-10 2021-12-10
Actual end date 2021-12-08 2021-12-08
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Available without restriction. Available without restriction.
Health Canada comments